# Exploratory Single-arm, Single-center Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer With Combination of Palizumab and SOX Regimen

> **NCT06036745** · PHASE2 · RECRUITING · sponsor: **Shanghai Minimally Invasive Surgery Center** · enrollment: 20 (estimated)

## Conditions studied

- Gastric Cancer Stage IIIB-IIIC

## Interventions

- **DRUG:** Pembrolizumab + SOX

## Key facts

- **NCT ID:** NCT06036745
- **Lead sponsor:** Shanghai Minimally Invasive Surgery Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-01
- **Primary completion:** 2023-07-01
- **Final completion:** 2026-07-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06036745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06036745, "Exploratory Single-arm, Single-center Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer With Combination of Palizumab and SOX Regimen". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06036745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*